Additional file 2: of A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase
Figure S1. Relative quantification of PTP4A3 (PRL-3) expression level in OCI-AML2 and MOLM-14 cells by qRT-PCR analysis. Figure S2. Representative immunoblot showing the levels of indicated proteins in OCI-AML2 (PRL-3 low) cells with different treatments. Figure S3. In vivo efficacy of VS-5584, ICG-001 single agent and combination treatment in mouse xenograft models transplanted OCI-AML2 cells. (PDF 246 kb)